Gabelli & Co Investment Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-700	Closed	-$221K	–	274
2023 Q1	$221K	Buy	+700	New	+$210K	0.04%	147
2022 Q1	–	Sell	-1,150	Closed	-$253K	–	526
2021 Q4	$253K	Sell	1,150 -73	-6%	-$14.2K	0.03%	318
2021 Q3	$222K	Buy	1,223 +150	+14%	+$29.3K	0.03%	335
2021 Q2	$216K	Buy	+1,073	New	+$224K	0.02%	327

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gabelli & Co Investment Advisers's VRTX Position: Q2 2023 in Review

Gabelli & Co Investment Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 700 shares — an estimated $221K sold.

Gabelli & Co Investment Advisers first reported a position in VRTX in Q2 2021 and held it in 4 quarters. The position peaked at $253K in Q4 2021. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Gabelli & Co Investment Advisers reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 700 Vertex Pharmaceuticals shares in Q2 2023, an estimated $221K.
Gabelli & Co Investment Advisers first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Gabelli & Co Investment Advisers's Vertex Pharmaceuticals position peaked at $253K in Q4 2021.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.